Get the Stockscreener App
4.41
4.26%
0.18
After Hours:
4.29
-0.12
-2.72%
Zentalis Pharmaceuticals Inc stock is traded at $4.41, with a volume of 768.60K.
It is up +4.26% in the last 24 hours and up +59.78% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.23
Open:
$4.26
24h Volume:
768.60K
Relative Volume:
0.42
Market Cap:
$313.93M
Revenue:
$26.87M
Net Income/Loss:
$-137.06M
P/E Ratio:
-2.311
EPS:
-1.9083
Net Cash Flow:
$-125.25M
1W Performance:
+7.82%
1M Performance:
+59.78%
6M Performance:
+244.53%
1Y Performance:
+250.00%
1-Day Range:
$4.195
$4.4394
1-Week Range:
$3.902
$4.4394
52-Week Range:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.41 | 301.12M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com Nigeria
Zentalis begins phase 3 trial of ovarian cancer drug - Investing.com
Zentalis starts global Phase 3 ovarian cancer trial against chemotherapy - Stock Titan
Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC - TradingView
Phase 3 ovarian cancer trial starts for Zentalis (Nasdaq: ZNTL) drug azenosertib - Stock Titan
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
ZNTL Technical Analysis | Trend, Signals & Chart Patterns | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
ZNTL: Zentalis Presents Promising Data on Azenosertib at AACR 20 - GuruFocus
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Zentalis presents preclinical data on cancer drug azenosertib By Investing.com - Investing.com Canada
Zentalis Highlights New Azenosertib Data in Breast Cancer - TipRanks
Zentalis Pharmaceuticals Presents Promising Preclinical Data on Azenosertib in Triple-Negative Breast Cancer and Insights on Cyclin E1-Positive Ovarian Cancer at AACR 2026 - Quiver Quantitative
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - ChartMill
Zentalis (Nasdaq: ZNTL) unveils azenosertib TNBC and Cyclin E1 ovarian cancer data at AACR 2026 - Stock Titan
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - ADVFN
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
Zentalis Stock Jumps as Guggenheim Lifts Price Target on Cancer Program Success - StocksToTrade
Zentalis Pharmaceuticals: Price Target Boost Sparks Speculative Momentum - timothysykes.com
Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans? - Moomoo
What's Behind The Surge In Zentalis Stock? - Sahm
Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Canada
This small-cap biotech stock just hit a near 22-month high – but this analyst still expects another 56% rally - MSN
What's behind the surge in Zentalis stock? - MSN
Today's Analyst Rating Update for ZNTL: Buy Rating Maintained wi - GuruFocus
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00 - MarketBeat
H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection By Investing.com - Investing.com Canada
Azenosertib Shows Promising Results in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer: Zentalis Advances Registration-Intent Trials - Minichart
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Bitget
Zentalis Advances Azenosertib Dose in DENALI Phase 2 - TipRanks
Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study - National Today
Zentalis selects 400mg dose for ovarian cancer drug trial By Investing.com - Investing.com UK
Zentalis selects 400mg QD 5:2 as pivotal azenosertib dose; DENALI topline due YE2026 - TradingView
Azenosertib 400mg dose to anchor Zentalis (NASDAQ: ZNTL) late-stage ovarian cancer trials - Stock Titan
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib - GlobeNewswire
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):